512 related articles for article (PubMed ID: 17441925)
1. Immunotherapy for metastatic renal cell carcinoma.
McDermott DF; Rini BI
BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
[No Abstract] [Full Text] [Related]
2. Immunotherapy for renal cell carcinoma.
Rosenblatt J; McDermott DF
Hematol Oncol Clin North Am; 2011 Aug; 25(4):793-812. PubMed ID: 21763968
[TBL] [Abstract][Full Text] [Related]
3. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
Parton M; Gore M; Eisen T
J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
[TBL] [Abstract][Full Text] [Related]
4. [Preliminary findings on clinical and immunological effects of subcutaneously administered interleukin-2 + alpha-interferon combination in the treatment of advanced renal carcinoma].
Buda F; Buda C; Croatto T; Costa B; Aragona P; Tuveri G
Recenti Prog Med; 1995; 86(7-8):304-5. PubMed ID: 7569288
[No Abstract] [Full Text] [Related]
5. Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, alpha-interferon (leucocyte) and tamoxifen.
Huland E; Heinzer H
Br J Cancer; 2000 Jan; 82(1):246-7. PubMed ID: 10638997
[No Abstract] [Full Text] [Related]
6. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of renal cell carcinoma with interferons].
Oya M
Nihon Rinsho; 2006 Jul; 64(7):1281-5. PubMed ID: 16838645
[TBL] [Abstract][Full Text] [Related]
8. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
Little B; Young M; Ho KJ
Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
[TBL] [Abstract][Full Text] [Related]
9. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
Figlin RA; Pierce WC; Belldegrun A
Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
[No Abstract] [Full Text] [Related]
10. [Immunotherapeutic treatment for metastatic renal carcinoma].
Hidalgo Pardo F; Gutiérrez Sanz-Gadea C; Rebassa Llull MJ; García Bueno JM; Mus Malleu A; Losada González GP; Ozonas Moragues M
Actas Urol Esp; 1998 Jan; 22(1):29-33. PubMed ID: 9542189
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy and prognostic factors.
Fumagalli LA; Brivio F
J Clin Oncol; 2006 Sep; 24(25):4218-9; author reply 4219-20. PubMed ID: 16943541
[No Abstract] [Full Text] [Related]
12. Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma.
Stadler WM; Vogelzang NJ
Semin Oncol; 1995 Feb; 22(1):67-73. PubMed ID: 7855621
[No Abstract] [Full Text] [Related]
13. Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma.
Kobayashi M; Suzuki K; Yashi M; Yuzawa M; Takayashiki N; Morita T
Anticancer Res; 2007; 27(2):1137-41. PubMed ID: 17465253
[TBL] [Abstract][Full Text] [Related]
14. Treatment of disseminated renal cell cancer with combinations of interleukin-2, lymphokine-activated killer cells, and alpha-interferon.
Stoter G; Goey SH; Batchelor D; Eggermont AM; Lamers C; Gratama JW; Bolhuis RL
Prog Clin Biol Res; 1992; 378():225-33. PubMed ID: 1301583
[No Abstract] [Full Text] [Related]
15. [Immunotherapy of metastatic renal cell cancer].
Manseck A; Wirth M
Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
[TBL] [Abstract][Full Text] [Related]
16. [The role of immunotherapy in metastatic cancer of the kidney].
Thiounn N
J Urol (Paris); 1994; 100(5):231-7. PubMed ID: 7730669
[TBL] [Abstract][Full Text] [Related]
17. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Ramsey S; Aitchison M
J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863
[No Abstract] [Full Text] [Related]
18. [Prognostic factors for predicting the success of immunotherapy in metastatic renal cell carcinoma].
Schmitz-Dräger BJ; Jankevicius F; Otto T
Urologe A; 1995 May; 34(3):195-9. PubMed ID: 7610511
[TBL] [Abstract][Full Text] [Related]
19. Metastatic renal cell carcinoma: systemic treatment.
Abi-Aad AS; deKernion JB
Acta Urol Belg; 1996 May; 64(2):3-8. PubMed ID: 8701805
[No Abstract] [Full Text] [Related]
20. Renal cell carcinoma and interleukin-2: what are the endpoints?
Figlin RA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S68-9. PubMed ID: 9457397
[No Abstract] [Full Text] [Related]
[Next] [New Search]
